Kevin Baumann
About Kevin Baumann
Kevin Baumann serves as the Director of Procurement at Arcus Biosciences, a position he has held since 2017. He previously worked as Associate Director of Purchasing at ChemoCentryx for 11 years and as Purchasing Manager at Genesoft Inc. for 2 years.
Work at Arcus Biosciences
Kevin Baumann has served as the Director of Procurement at Arcus Biosciences since 2017. In this role, he is responsible for overseeing the procurement processes and ensuring the efficient acquisition of goods and services necessary for the company's operations. Arcus Biosciences, located in Hayward, California, focuses on developing innovative cancer therapies. Baumann's expertise in procurement supports the company's mission by optimizing supply chain management and fostering relationships with vendors.
Previous Experience at ChemoCentryx
Before joining Arcus Biosciences, Kevin Baumann worked at ChemoCentryx as the Associate Director of Purchasing from 2006 to 2017. During his 11 years at the company, he played a key role in managing purchasing activities and contributing to the overall procurement strategy. His experience at ChemoCentryx provided him with valuable insights into the pharmaceutical industry and enhanced his skills in vendor negotiation and supply chain management.
Early Career at Genesoft Inc.
Kevin Baumann began his career at Genesoft Inc., where he held the position of Purchasing Manager from 2000 to 2002. In this role, he was responsible for managing purchasing operations and ensuring that the company had the necessary materials for its projects. His early experience in procurement laid the foundation for his subsequent roles in the industry.
Education and Expertise
While specific educational details are not provided, Kevin Baumann's extensive experience in procurement and purchasing across multiple organizations demonstrates his expertise in supply chain management. His roles have involved strategic sourcing, vendor management, and optimizing procurement processes, which are critical skills in the pharmaceutical and biotechnology sectors.